Rezon Bio Appoints Dr. Ralf Otto as Chief Operating Officer to Strengthen Global CDMO Expansion Strategy
Rezon Bio, a science-driven European biologics contract development and manufacturing organization (CDMO), has announced the appointment of Dr. Ralf Otto, PhD, as its new Chief Operating Officer (COO), effective June 1, 2026. The leadership addition comes as the company accelerates its expansion strategy and strengthens its position in the global biologics manufacturing landscape.
In his new role, Dr. Otto will oversee Rezon Bio’s core operational functions, including clinical and commercial cGMP manufacturing, process development, quality systems, engineering, and broader business operations. His responsibilities will span the company’s integrated end-to-end CDMO platform, which supports biopharmaceutical clients from early-stage development through commercial production.
The appointment reflects Rezon Bio’s ambition to scale its capabilities, enhance operational efficiency, and expand its global client base at a time of increasing demand for cost-effective and high-quality biologics manufacturing services.
Strengthening Operational Leadership for the Next Growth Phase
Rezon Bio is entering a new phase of growth focused on expanding access to biologics and biosimilars through a combination of scientific expertise, scalable infrastructure, and operational excellence. The company aims to enhance its competitive position in the global CDMO market by offering integrated services that support faster development timelines and more efficient manufacturing solutions.
Dr. Otto’s appointment is intended to reinforce this strategy by bringing in a leader with extensive experience in biologics manufacturing, global operations, and organizational transformation. His leadership is expected to help streamline production processes, improve cross-functional coordination, and support Rezon Bio’s long-term objective of delivering reliable, high-quality services to pharmaceutical and biotechnology partners worldwide.
A Veteran Leader in Biologics Manufacturing and CDMO Operations
Dr. Ralf Otto brings more than 25 years of international experience across the biopharmaceutical and CDMO industries, with a strong track record in biologics development, large-scale manufacturing, and operational transformation across both Europe and the United States.
Throughout his career, he has held senior leadership roles overseeing clinical and commercial cGMP manufacturing operations, technology transfer programs, and manufacturing scale-up initiatives. His expertise spans mammalian cell culture systems, biologics process development, and the implementation of operational excellence frameworks designed to improve efficiency and scalability in complex manufacturing environments.
Dr. Otto has also been closely involved in CDMO transformation initiatives, helping organizations evolve into more integrated, client-focused service providers capable of supporting end-to-end biologics development. His background includes leading global supply operations and driving organizational restructuring efforts aimed at enhancing performance and expanding service capabilities.
Leadership Commentary on the Appointment
Dr. Adriana Kiędzierska-Mencfeld, PhD, Chief Executive Officer of Rezon Bio, emphasized the strategic importance of Dr. Otto’s appointment as the company continues to scale its operations.
She highlighted his extensive international experience across biologics manufacturing and operational transformation, noting that his leadership style is both pragmatic and execution-focused. According to Dr. Kiędzierska-Mencfeld, these qualities will be instrumental in strengthening Rezon Bio’s integrated capabilities and enhancing service delivery across the organization.
She added that Dr. Otto’s appointment aligns with the company’s broader mission to improve scalability, reliability, and client experience across the biologics development lifecycle. As demand for CDMO services continues to grow globally, Rezon Bio is positioning itself to meet the evolving needs of biopharmaceutical companies seeking efficient and high-quality manufacturing partners.
Dr. Otto’s Perspective on Joining Rezon Bio
Dr. Ralf Otto expressed enthusiasm about joining Rezon Bio at a pivotal stage in its development. He highlighted the company’s strong scientific foundation, long-term strategic vision, and committed workforce as key factors that attracted him to the role.
He emphasized that the biopharmaceutical industry is increasingly reliant on CDMOs that can offer both technical expertise and cost competitiveness while maintaining high standards of quality and regulatory compliance. According to Dr. Otto, Rezon Bio is well-positioned to meet these demands through its integrated development and manufacturing model.
In his new role, he stated that his focus will be on ensuring a seamless, responsive, and high-quality experience for clients across the entire biologics lifecycle, from early development through commercial supply. He also underscored the importance of operational reliability and scalability in supporting innovation within the biologics sector.
Extensive Global Experience in Biopharmaceutical Operations
Before joining Rezon Bio, Dr. Otto held several senior leadership positions across leading biopharmaceutical companies and global CDMOs, where he played a key role in shaping manufacturing strategies and driving organizational growth.
He previously worked at Boehringer Ingelheim BioXcellence, where he led large-scale mammalian cell culture manufacturing operations supporting both clinical and commercial biologics supply. In this role, he was responsible for overseeing complex production systems and ensuring compliance with stringent global quality standards.
Dr. Otto later served as General Manager and Site Head in Fremont, California, where he led the transformation of the site into a multi-product CDMO facility. His leadership focused on operational excellence, capacity expansion, and improving the site’s ability to support a broader range of client programs.
At Rentschler Biopharma Inc, he served first as Chief Operating Officer and later as President and Chief Executive Officer. During his tenure, he drove significant capability expansion and operational transformation initiatives, strengthening the company’s integrated biologics development and manufacturing services and enhancing its global competitiveness.
In addition to his operational leadership roles, Dr. Otto also worked as a Partner at McKinsey & Company, where he advised global biopharmaceutical companies, CROs, and CDMOs on strategy, operational transformation, organizational design, and capability building. His consulting work focused on helping life sciences organizations improve efficiency, scale operations, and adapt to rapidly evolving market conditions.
Dr. Otto holds a doctorate in biotechnology from the University of Stuttgart, underscoring his strong academic foundation in life sciences and bioprocess engineering.
Supporting Rezon Bio’s Integrated CDMO Strategy
Rezon Bio operates as a fully integrated CDMO, offering end-to-end services that span biologics development, clinical manufacturing, and commercial-scale production. The company’s platform is designed to support biopharmaceutical clients across multiple stages of the product lifecycle, enabling faster development timelines and more efficient scale-up processes.
As the biologics industry continues to expand, CDMOs are playing an increasingly important role in enabling innovation by providing the infrastructure and expertise required to manufacture complex therapies at scale. Rezon Bio’s strategy is centered on enhancing flexibility, improving cost competitiveness, and delivering consistent quality across its global operations.
Dr. Otto’s appointment is expected to further strengthen this strategy by enhancing operational integration and reinforcing the company’s ability to deliver high-performance manufacturing solutions to its clients.
Positioning for Growth in a Competitive CDMO Market
The global CDMO market is experiencing sustained growth driven by rising demand for biologics, biosimilars, and advanced therapies. Pharmaceutical and biotechnology companies are increasingly outsourcing manufacturing and development activities to specialized partners with the expertise and infrastructure required to support complex production needs.
In this competitive environment, CDMOs are differentiating themselves through operational efficiency, technological capabilities, global footprint, and quality systems. Rezon Bio’s focus on integrated services and scalable manufacturing positions it to compete effectively in this evolving landscape.
By appointing an experienced industry leader with deep expertise in biologics manufacturing and CDMO transformation, the company is reinforcing its commitment to operational excellence and long-term growth.
With Dr. Ralf Otto set to assume the role of Chief Operating Officer in 2026, Rezon Bio is strengthening its leadership team as it prepares for its next stage of expansion. His extensive experience in global biopharmaceutical operations, combined with his background in both industry and consulting, is expected to play a central role in shaping the company’s future development.
As Rezon Bio continues to expand its global presence and enhance its service offerings, the company is positioning itself as a key player in the biologics CDMO sector. The addition of Dr. Otto underscores its commitment to delivering high-quality, scalable, and cost-effective manufacturing solutions that support innovation across the life sciences industry.
About Rezon Bio
Rezon Bio is a science-driven contract development and manufacturing organization (CDMO) specializing in the development and manufacturing of mammalian biologics. Headquartered in Poland, Rezon Bio offers integrated solutions spanning cell line development, commercial drug substance manufacturing, and drug product development, with state-of-the-art facilities, world-class teams, and a proven track record of regulatory and commercial success. Grounded in Polpharma Biologic’s legacy of excellence in biosimilars development and manufacturing, Rezon Bio is committed to delivering value without compromise through innovation, collaboration, analytical excellence, and dedication to patients worldwide.
